Vol. 19/No. 11 | OncologyLive

Qualified Clinical Data Registries Help Practices Meet MIPS Requirements

May 26, 2018

To ease the administrative burden, CMS has facilitated the collection and processing of information by allowing the formulation of Qualified Clinical Data Registries, which collect data on quality measures from individual providers and group practitioners.

Pan-Cancer Atlas Provides Argument for Molecular Classification

May 23, 2018

The Cancer Genome Atlas Research Network has completed an integrative molecular analysis of roughly 10,000 tumor specimens and identified cancer subtypes that reflect shared molecular characteristics across traditional anatomic boundaries.

Reinventing Benchmarking for the Value Era

May 23, 2018

Benchmarking has historically been difficult in oncology because of barriers to the flow of information and the complexities of care. However, such performance comparisons are now becoming a part of payment models, and practices realize they need comparative data to understand how well they perform.

A Whirlwind of Change in Lung Cancer

May 22, 2018

Novel combination regimens anchored by pembrolizumab (Keytruda), atezolizumab (Tecentriq), or nivolumab (Opdivo) are opening the door to new options and an opportunity to personalize therapy in non–small cell lung cancer.

Task Force Changes Stance on Value of PSA Test

May 21, 2018

The US Preventive Services Task Force has concluded that there is a small mortality benefit associated with prostate-specific antigen-based prostate cancer screening for men aged 55 to 69 years, a departure from earlier guidance.

Study Findings Complicate the Paradigm for Hormone-Sensitive Prostate Cancer

May 21, 2018

Data from recent trials in metastatic hormone-sensitive prostate cancer have demonstrated the heterogeneous nature of prostate cancer and its subtypes, highlighting the importance of a more cautious approach in choosing therapies for patients.